Title page

Title: Population-level hypertension control rate in India: A systematic review and meta-

analysis of community based non-interventional studies, 2001-2020

Authors' names, academic degrees, and affiliations

Shaffi Fazaludeen Koya MBBS, MPH¹ Zarin Pilakkadavath MBBS, DNB, MRCGP[INT]² Tom Wilson MBBS, MD³ Praseeda Chandran MBBS, MD³ Serin Kuriakose, MBBS, DNB⁴ Suni K Akbar MBBS,DNB⁵ Althaf Ali MBBS, MD³

¹Boston University School of Public Health, Boston, Massachusetts, USA

²Boston University School of Medicine, Boston, Massachusetts, USA

³Department of Community Medicine, Manjeri Medical College, Kerala, India

⁴National Centre for Disease Control, New Delhi, Delhi, India

⁵KIMS Al-Shifa Specialty Hospital, Perinthalmanna, Kerala, India

Short title: Hypertension control in India-systematic review and meta-analysis

Name, email address, and complete address of corresponding author

Shaffi Fazaludeen Koya MBBS, MPH 715 Albany St, Boston University School of Public Health, Massachusetts, USA fmshaffi@bu.edu

Key words: Hypertension control, risk factors, systematic review, meta-analysis, determinants

Abstract

Background: Hypertension is a significant contributor to mortality in India. Adequate control of hypertension is important to prevent cardiovascular morbidity and mortality.

Methods: We conducted a systematic review and meta-analysis of community-based, non-interventional studies published between 2001 and 2020. We screened records from PubMed, Embase, and Web of Science databases, extracted data, and assessed risk of bias. We conducted random-effects meta-analysis to provide overall summary estimates and subgroup estimates, and mixed-effects meta-regression with sex, region, and study period as covariates. The risk of bias was assessed using modified New Castle-Ottawa scales. This study is registered with PROSPERO, CRD42021267973.

Results: The systematic review included 37 studies (n=170,631 hypertensive patients). Twelve studies (32%) reported poorer control rates among males than females, four studies (11%) reported poorer control rates among rural patients, while very few studies reported differences across socioeconomic variables. The overall control rate was 33.2% (n=84,485, 95% CI=27.9,38.6) with substantial heterogeneity (I2=99.1%, \chi^2= 3003.91, 95% CI=98.9,99.2; p <0.001). Unadjusted sub-group analysis showed significantly different hypertension control rates across regions (n=12,938, p=0.003) but not across study periods (n= 84,485, p=0.22), or sex (n= 81,197, p=0.22). Meta-regression showed that control rates increased by 14.7% during 2011-2020 compared to 2001-2010 (95%CI=5.8, 23.5, p=0.0021), and was 26.3% higher in the south

(95%CI=12.6, 39.9, p=0.0005) and 15.9% higher in the west (95%CI=3.4, 31.4, p=0.0456) compared to the east. The control rates did not differ by sex.

Conclusion: Hypertension is adequately controlled only among one-third of patients in India. The control rate has improved during 2011-2020 compared to 2001-2010, but substantial differences exist across regions. Very few studies examined relevant socioeconomic factors relevant to hypertension control. India needs more studies at the community level to understand the health system and socioeconomic factors that determine uncontrolled hypertension in India.

Introduction

Hypertension is a major modifiable risk factor for cardiovascular diseases (CVD), making it one of the major contributors of premature death and morbidity.^{1,2} The overall age adjusted prevalence of hypertension has plateaued, but the absolute number has doubled due to an increasing trend in low-middle income countries (LMICs).³ Globally, only 21% known hypertensive patients had their blood pressure under control.¹ Hypertension is the most important risk factor of death and disability in India.^{4,5} The recently concluded National Family Health Survey (NFHS-5, 2019-20) reported hypertension prevalence to be 23.9% and 21.3% among men and women up from 19% and 17% respectively from the previous round.⁶

Pharmacological intervention remains the mainstay of hypertension management, and medication adherence is a cost effective way to reduce mortality and complications.⁷ Close to 80% of NCD patients in India seek medical care from the private sector, where there are no mechanisms to actively monitor drug adherence.⁸ Besides, the high out-of-pocket expenditure and lack of insurance coverage for out-patient services and drugs reduces access to anti-hypertensive medication, increasing the risk of uncontrolled hypertension.⁹

There have been no published systematic reviews or meta-analysis in the recent period, and the previous review did not explore the changes in control rates over years. This review tries to answer the following questions:

1. What is the overall hypertension control rate in India?

- 2. What are the sex- and region- specific estimates of control rates?
- 3. Whether control rate in India has improved after the launch of India's NCD control

program in 2010?

Methods

This systematic review was performed to according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations.¹⁰ Institutional review board approval was not required for this study since no patient identifiers were involved. The review is registered with the PROSPERO database (CRD42021267973).

Search strategy

We searched PubMed, Web of Science, and Embase and are reported as of 31 July 2021. The search strategy (see Supplement (S1) used a combination of MeSH and non-MeSH terms for 'hypertension' and 'control'. We included community-based non-interventional studies published between 1 January 2001 and 31 December 2020.

Study eligibility

We excluded studies on secondary hypertension, interventional studies, qualitative studies, hospital-based studies, commentaries, and reviews. Studies that used

convenient sampling and those that did not provide the number of known cases of hypertension were excluded.

Data extraction

After excluding duplicates, two authors (SFK and ZP) screened all the titles and abstracts using Rayyan online collaborative systematic review platform(Figure 1).¹¹ Each full text article was read by at least two authors following the inclusion criteria. Thereafter, two authors reviewed independently and extracted the following relevant information from each paper: authors, published year, study/data collection year, state, geographical area covered(rural/urban), sample size (sex-disaggregated), definitions of hypertension and control, total hypertension cases and percentage (disaggregated across sex and rural/urban), control rates (number and percentage, disaggregated numbers and percentages across sex), and reported difference in control rates across rural/urban, education levels, income status (rich/poor), and antihypertension medication status. Disagreements between reviewers were sorted out through discussions and pending discrepancies were resolved by the lead reviewer.

We excluded 121 articles due to the following reasons: missing data, wrong article type, wrong population, wrong period, intervention studies, or full paper not available. Of the 37 articles in the review a subset of 29 articles were included in the meta-analysis (Supplement, S2) after excluding eight studies with sample size less than 100.

Figure 1: PRISMA flowchart showing study selection

Definitions used

We included known primary hypertensive adult population (18 years and above) irrespective of medication history in our denominator. We defined hypertension control as systolic blood pressure (SBP) less than 140 mmHg and diastolic blood pressure (DBP) less than 90 mmHg (JNC 7) among these known patients.¹²

Study quality

We adapted Newcastle-Ottawa scales¹³ to assess the study quality on a scale of zero to six, across the following four criteria: selection, comparability, completeness, and statistical test. After one of the reviewers scored each paper the lead reviewer reviewed them again to decide on the score and classification. Studies that scored four or more were classified "low risk of bias" and others were classified "high risk of bias". The median score was four; five studies got a full score of six and one study received zero. There were 19 "low risk of bias" studies and 18 "high risk of bias" studies. (Figure S3). The detailed method used for scoring and the score for each paper are shown in the supplement (S4).

Statistical analysis

We conducted all the analysis using R software version 4.1.1 (R Core Team, 2020), and the 'metafor' and 'meta' packages were used for meta-analysis. First, we described the study characteristics using numbers and proportions and reported hypertension control rates in percentages. Second, we summarized the reported difference in control rates across sex, geography (rural/urban), education levels, income status, and by antihypertension medication status. The p-values or 95% confidence intervals were considered to decide on differences between reported rates. Finally, we did the meta-analysis and meta-regression. The summary effect size statistic for analysis- the untransformed (raw) hypertension control rates- was found to be normally distributed using Q-Q plot. Since the studies came from different regions of the country having different population characteristics, we anticipated heterogeneity and therefore decided to use random effect model *a priori*.

We used multiple methods to examine heterogeneity in our data. First, we created forest plot to visually inspect the data. Second, we looked at the total amount of systematic differences in effects across studies calculated as the between-study variance (heterogeneity, measured as τ^2 (tau-squared)) and standard deviation (τ). We used the DerSimonian-Laird estimator¹⁴ to calculate the heterogeneity variance (τ^2) and Jackson method¹⁵ to calculate its 95% Confidence Intervals (CI) with Knapp-Hartung adjustments.¹⁶ Third, we estimated the I² statistic (with 95% CIs)¹⁷ which is the ratio of

observed heterogeneity (between-study variance) and the total observed variance (sum of within-study variance due to sampling error and between-study variance). Finally, we conducted a formal χ^2 test with a Cochran's Q statistic, to test if all studies share the common effect size.¹⁸ All statistical tests were two sided and p-value was fixed at 0.05.

Results

Study characteristics

Table 1 shows the overall features of the studies included in the review. The systematic review includes 37 studies (35 cross-sectional and two cohort studies).^{19–54} The total sample was 870,659 (80% females) including 170,631 hypertensive patients. The mean hypertension prevalence across studies was 35.6% (SD= 14.6) which did not vary between males and females.

Table 1: Characteristics of studies included in the systematic review

Sixteen studies (43%) reported data for the period 2001-2010 while the remaining 21 studies had data for the period 2011-2020. Forty one percent studies had data only from rural areas, and five studies (14%) reported a higher prevalence of hypertension in urban areas compared to rural areas. 16 studies (43%) were from southern states in India, most studies (n=34, 92%) had both males and females, and fourteen (38%) studies reported a higher prevalence of hypertension in males.

Reporting of control rates

There were 12 studies (32%) that reported poorer control rates among males than females ^{20,32,33,36,41,43,45,49–51,53,54} while only three studies showed females to have a poorer control rate than males.^{24,31,44} Four studies (11%) reported poorer control rates among rural patients ^{43,45,47,54} while two studies showed there was no difference in control rate between rural and urban patients.^{48,51} Two studies showed poorer control rates based on medication status which showed no difference between the groups.²⁹ One study⁵⁰ showed poorer control in the less educated group while three studies found no difference across educational levels.^{46,48,54}

Meta-analysis

We used random effects model to calculate the summary effect size, i.e., the weighted average of the observed control rates in 29 studies. The inverse of the total variance of the study was used to weigh each study. The output revealed that τ^2 is 0.02 (95% CI=0.01, 0.05), τ = 12.7% (95% CI= 9.9,22.2), I² is 99.1% (95% CI=98.9,99.2), and the Q-statistic (df=28) is 3003.9 (p<0.0001), all of which suggested high heterogeneity in the effect sizes. To identify outliers and influential studies causing heterogeneity, we used a diagnostic Baujat plot (Supplement S5) which showed two studies with studentized residuals (z- values) greater than two.^{28,45} To further investigate, we performed a set of leave-one-out diagnostic tests (Supplement S6) to calculate the

summary values of hypertension control rates by excluding one study each at a time from the analysis. However, the results and subsequent visualization or residuals (Supplement S7) did not show any significant difference in control rates with the exclusion of the two studies. So, we decided against removing any studies from the model.

Overall hypertension control rate

The overall random effects model with Hartung-Knapp adjustment shows that the mean rate of hypertension control in India during 2001-2011 was 33.2% (95% CI= 27.9, 38.6). (Figure 2) In comparison, a post-hoc estimate of the fixed effect model shows a pooled control rate of 17.0% (95% CI=16.8%, 17.2%) lower than our estimates using random effects model. The wide difference between the models also substantiates our decision to use random-effects model. Our 95% prediction interval 6.7% - 59.8% is wide reflecting high levels of heterogeneity.

Figure 2: Forest plot showing the unadjusted hypertension control rates

Subgroup analysis

We conducted subgroup analysis to understand the heterogeneity and the results are summarized as forest plot (Figure 3) and table (Supplement S8). To test if the hypertension rates have improved over time, we compared studies conducted in the first ten years (2001-2010) with studies conducted in the second ten years (2011-2020). We computed the summary effects for each subgroup under the random effects model. Since systematic reasons like differences in population across states can still produce different values of the within-group τ^2 values, we applied separate estimates of τ^2 for each subgroup, effectively resulting in an independent meta-analysis of the subgroups. We found that the control rates have improved over the years (35.8% in 2011-2020 versus 29.6% in 2001-2010), but the improvement was not statistically significant (p=0.22), and there was significant heterogeneity (τ^2 = 0.01, p<0.001).

Figure 3: Forest plot showing sub-group analysis across region, study period and sex.

We conducted meta-analysis of 81,197 patients (68,928 females and 12,269 males) pooled from 20 studies with sex-segregated data. The results showed that females had better control rates than males, but the difference was not statistically significant (34.2% [95% CI=26.6, 41.9] for females versus 28.2% [95% CI=21.0, 35.4] for males). Substantial heterogeneity remained (τ^2 = 0.01, p< 0.001). The control rates of females improved by 11% points between 2001-2010 and 2011-2020 whereas the control rates for males improved only by 7% points during the same period. However, these changes were not statistically significant.

In the subgroup analysis for regions, we avoided studies with data from multiple regions and analyzed 12,938 known hypertensive patients from 24 studies (13 studies from south, 4 studies each from north and east, and 3 from west). Control rates were significantly different across regions (p= 0.003). The south (39.3%) and west (32.9%) regions reported higher control rates compared to the north (25.8%) and the east (20.7%).

Meta-regression

To control rate for differences in region, period of study, and sex, we conducted a mixed-effects meta-regression^{55,56} using the model equation:

$$\widehat{\theta}_{k} = \theta + \beta x_{k} + \varepsilon_{k} + \zeta_{k}$$

where $\hat{\theta}_k$ is the observed effect-size (hypertension control rate) with *k* studies, θ is the intercept, β is the regression coefficient for the variable *x*, ε_k is the sampling error through which the effect size of a study deviates from its true effect, and ζ_k is the error arising due to heterogeneity. We built a multiple regression model with the following variables: region(north, east, south, west), period of study (2001-'10 vs 2011-'20), and sex(male, female), after excluding studies involving multiple regions. (Table 2). The model accounted for 52% of heterogeneity and showed that control rate did not differ across sex when controlled for region and period of study. The model also showed that when adjusted for regional and sex differences, the rate of control improved by 14.7% points from 2001-2010 to 2011-2020 (p< 0.01). Southern region reported 26.3% (95% CI= 12.6, 39.9, P= 0.0005) and western region reported 15.9%(95% CI=3.4, 31.4, p= 0.0456) higher control rate compared to the eastern region.

Table 2: Meta-regression model: hypertension control rates in India, 2001-2020

Sensitivity analysis

We conducted two sensitivity analyses. The first analysis was done by avoiding four studies with only elderly population. In the second sensitivity analysis, we included only "low risk of bias" studies. The resultant models did not differ in overall control rates from the original model.

Publication bias

With prevalence as the outcome measure we do not expect publication bias arising from study design related significance level.⁵⁷ The funnel plot asymmetry (Supplement, S9) and the subsequent Egger's⁵⁸ regression test result (t=5.6, p< 0.0001) may not be explained by publication bias but rather by the high level of heterogeneity and quality of studies themselves.

Discussion

To our understanding this is the first meta-analysis that examined the changes in population-level hypertension control rates in India over the years. We compared the control rates in one decade preceding and one decade succeeding the launch of India's national program for NCDs. There are four key findings from our study.

First, only one-third of known hypertensive patients in India have adequate blood pressure control despite the launch of a national program to control NCD in 2010. The only previously published meta-analysis of community-level hypertension control in India with data from 1950 to 2013 showed a control rate of 10.7% for rural India and 20.2% for urban India.⁵⁹ Though the control rate that we report is substantially higher, the low rate of 33.2% is still a concern. This is especially true considering that only 50% of patients in 15–49-year age group in India knew their hypertension status as per the NFHS-4 data (2015-16).⁵⁴ India's NCD program needs serious evaluation to see how far is it meeting its public health objectives to control hypertension.⁶⁰ Interrupted supply of medicines, inadequate health education and low health literacy can have a synergistic effect leading to incomplete treatment or non-compliance. India also started a multipartner initiative, the India hypertension control initiative in 2017, to strengthen the public health measures to control hypertension. A recent study analyzing the initial cohort from four Indian states showed significant improvement in blood pressure control (59.8% in follow up versus 26.3% at baseline), more so in the primary care settings that shows that better blood pressure control can be achieved through scalable public health programs.⁶¹ Comparing with recent literature, a recent cross-sectional study of 1.1 million adults across 44 LMICs including India showed that the control rate for hypertension was only 10.3%.⁶² A systematic review and meta-analysis from Nepal showed a hypertension control rate of 38% among treated hypertensives with only marginal improvement over years.⁶³ The most recent data from Pakistan shows that only half of diagnosed hypertensive patients are treated and only 12.5% are controlled.⁶⁴

Second, significant regional differences exist in the hypertension control, even when limited by the fewer number of studies in west and north India compared to south. South India showed better control rates after adjusting for sex and study period. Kerala and Tamil Nadu reported the highest rates of control, after excluding the very high rates reported by one study each from Punjab and Andhra Pradesh. The difference in health system capacity to detect and treat hypertension varies across the country as much as the level of awareness about the disease, its prevention, and control vary. Treatment adherence and access to medicine are key determinants of adequate control. Veena et. al reported that among those with controlled hypertension, 23.7% subjects monitored blood pressure 2-4 times a year while 67.30% never monitored their blood pressure.³⁵ Adherence to medications was examined in only one study⁴⁶ in our review that showed significant association with control rate. In addition, we found only one study²⁹ (conducted among elderly) that compared control status based on medication status, while no study was found to examine the access to antihypertensive medicines. A recent study had shown that low availability of generic medicines in public and private sector and high costs are major barriers to antihypertensive control including in India.⁶⁵ Another study reported that around 70% of the estimated proportion of adults with hypertension did not receive antihypertensive drugs in 2018.⁶⁶

Third, very few studies reported lifestyle and risk factors associated with poor control rates. Among them, Tripathy et. al⁴⁵ reported that uncontrolled hypertension was more frequent among obese patients, patients with sedentary lifestyle, and diabetic patients.

Thankappan et. al⁴¹ also found poor blood pressure control among diabetics and obese patients. Diet and smoking were reported as predictors in one study⁴⁶ while greater per cent body fat was the only factor reported in another,²⁸ while good family support to self-care was reported by a third study.⁴⁶

Finally, very few studies had data on key social determinants of hypertension control like income, wealth, and caste. Data on income or wealth and education were unavailable in 89% of studies, while no studies had data on caste differences on hypertension control. A recent study (not included in our review) showed 13 percent point gap in control rate between the rich and the poor and clear disadvantage for scheduled castes, tribes and backward communities.⁶⁷ The previous meta-analysis from India reported significant differences in rural and urban on awareness and control levels while no significant difference was noted for percentage treated.⁶¹ In our review we found two studies that reported no difference between urban and rural population while four studies reported rural populations to have poorer control.

Limitations

We included only studies published until 31 December 2020, and as such we would have missed studies that have been published afterwards. Our study did not explain differences across age groups, as we were limited by the data availability in the reviewed papers.

Conclusion

India needs far more studies at the community level to understand the epidemiology of hypertension control, especially in north and west India. Well-designed studies that ensure quality of data will help us to better understand the differences in control rates across regions. Studies should examine relevant health-system, socio-economic, and lifestyle factors that determine adequate control levels so that policies and programs can be designed to specifically address the key determinants of uncontrolled hypertension in India.

Acknowledgments: None

Sources of Funding: None

Disclosures: None to declare

Tables

Table 1: Summary characteristics of studies included in the systematic review

Characteristics	2001-2010 , N = 16 ¹	2011-2020 , N = 21 ¹	Overall , $N = 37^{1}$
Sex			
Both	15 (94%)	19 (90%)	34 (100%)
Female	1 (6.2%)	1 (4.8%)	2 (100%)
Male	0 (0%)	1 (4.8%)	1 (100%)
Age group			
15 years and above	1 (6.2%)	2 (9.5%)	3 (100%)
Adults (18 years +)	13 (81%)	16 (76%)	29 (100%)
Elderly(60 years+)	2 (12%)	3 (14%)	5 (100%)
Region			
North	1 (6.2%)	5 (24%)	6 (100%)
East	3 (19%)	2 (9.5%)	5 (100%)
South	5 (31%)	2 (9.5%)	7 (100%)
West	6 (38%)	10 (48%)	16 (v%)
Multi-region	1 (6.2%)	2 (9.5%)	3 (100%)
Area			
Both	4 (25%)	7 (33%)	11 (100%)
Rural	6 (38%)	9 (43%)	15 (100%)
Urban	6 (38%)	5 (24%)	11 (100%)
Period of publication			
2001-2010	8 (50%)	0 (0%)	8 (100%)
2011-2020	8 (50%)	21 (100%)	29 (100%)
Study design			
Cohort	2 (12%)	0 (0%)	2 (100%)
Cross-sectional	14 (88%)	21 (100%)	35 (100%)
Sampling method			
Census	1 (6.2%)	2 (9.5%)	3 (100%)
Cluster sampling	8 (50%)	6 (29%)	14 (100%)
Simple random sampling	4 (25%)	4 (19%)	8 (100%)
Systematic random sampling	3 (19%)	9 (43%)	12 (100%)
Hypertension prevalence			
Sex			
Female had higher prevalence	3 (19%)	5 (24%)	8 (100%)
Prevalence is similar	4 (25%)	3 (14%)	7 (100%)
Male had higher prevalence	6 (38%)	8 (38%)	14 (100%)
Not reported	3 (38%)	5(63%)	8(100%)

Region			
Prevalence is similar un urban and			
rural areas	0 (0%)	1 (100%)	1 (100%)
Urban areas reported higher	2(409/)	2(60)()	E (1009/)
prevalence	2 (40%)	3 (60%)	5 (100%)
Not reported	14(45%)	17(55%)	31(100%)
Hypertension control rates			
Sex			
Males have poorer control	5 (42%)	7 (58%)	12 (100%)
Females have poorer control	2 (67%)	1 (33%)	3 (100%)
No difference	3 (43%)	4 (57%)	7 (100%)
Not reported	6(40%)	9(60%)	15(100%)
Region			· · ·
Rural patients have poorer control	1 (25%)	3 (75%)	4 (100%)
No difference	1 (50%)	1 (50%)	2 (100%)
Not reported	14(45%)	17(55%)	31(100%)
Income/wealth			
Low income/wealth groups have			
poorer control	1 (50%)	1 (50%)	2 (100%)
No difference	1 (50%)	1 (50%)	2 (100%)
Not reported	14 (42%)	19 (58%)	33 (100%)
Education levels			
Less educated have poorer control	1 (100%)	0 (0%)	1 (100%)
No difference	0 (0%)	3 (100%)	3 (100%)
Not reported	15 (45%)	18 (55%)	33 (100%)
Treatment/not on treatment			, /
No difference based on treatment			
status	0 (0%)	1 (100%)	1 (100%)
Not reported	16 (44%)	20 (56%)	36 (100%)
¹ n (%)			

	Effect estimate	95% CI	Standard error	t-value	p- value
Intercept	9.2	-4.3, 22.7	6.6	1.39	0.1743
Region: North	10.1	-4.6, 24.7	7.1	1.41	0.1687
Region: South	26.3	12.6, 39.9***	6.6	3.96	0.0005
Region: West	15.9	3.4, 31.4*	7.5	2.10	0.0456
Period: 2011-2020	14.7	5.8, 23.5**	4.3	3.43	0.0021
Sex: Male	-4.7	-13.5, 4.0	4.3	-1.11	0.279

Table 2: Meta-regression model: hypertension control rates in India, 2001-2020

Significance codes: '***' 0.001 '**' 0.01 '*' 0.05

Reference:

- 1. Global Health Estimates: Life expectancy and leading causes of death and disability. Accessed January 2, 2022. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates
- Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. J Am Coll Cardiol. 2020;76(25):2982-3021. doi:10.1016/j.jacc.2020.11.010
- 3. Mills KT, Bundy JD, Kelly TN, et al. Global Disparities of Hypertension Prevalence and Control. *Circulation*. 2016;134(6):441-450. doi:10.1161/CIRCULATIONAHA.115.018912
- 4. GBD India Compare | IHME Viz Hub. Accessed January 2, 2022. http://vizhub.healthdata.org/gbd-compare/india
- 5. Indian Council of Medical Research, Public Health Foundation of India, University of Washington, Institute for Health Metrics and Evaluation. *India: Health of the Nation's States* : *The India State-Level Disease Burden Initiative* : Disease Burden Trends in the States of India, 1990 to 2016.; 2017.
- 6. International Institute for Population Sciences. *National Family Health Survey (NFHS-5),* 2019-21. International Institute for Population Sciences (IIPS) and ICF.; 2021. Accessed January 2, 2022. http://rchiips.org/nfhs/NFHS-5_FCTS/India.pdf
- World Health Organization. *Guideline for the Pharmacological Treatment of Hypertension in Adults*. World Health Organization; 2021. Accessed January 2, 2022. https://apps.who.int/iris/handle/10665/344424
- 8. Engelgau MM, Karan A, Mahal A. The Economic impact of Non-communicable Diseases on households in India. *Glob Health*. 2012;8(1):9. doi:10.1186/1744-8603-8-9
- 9. Choudhry NK, Kronish IM, Vongpatanasin W, et al. Medication Adherence and Blood Pressure Control: A Scientific Statement From the American Heart Association. *Hypertension*. 2022;79(1):e1-e14. doi:10.1161/HYP.00000000000203
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*. 2009;339:b2535. doi:10.1136/bmj.b2535
- 11. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. *Syst Rev.* 2016;5(1):210. doi:10.1186/s13643-016-0384-4
- 12. NHLBI. The Seventh Report of the Joint National Committee On National High Blood Pressure Education Program Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.; 2004. https://www.nhlbi.nih.gov/files/docs/guidelines/jnc7full.pdf


- Modesti PA, Reboldi G, Cappuccio FP, et al. Panethnic Differences in Blood Pressure in Europe: A Systematic Review and Meta-Analysis. *PLOS ONE*. 2016;11(1):e0147601. doi:10.1371/journal.pone.0147601
- 14. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7(3):177-188. doi:10.1016/0197-2456(86)90046-2
- 15. Jackson D, Bowden J. Confidence intervals for the between-study variance in random-effects meta-analysis using generalised heterogeneity statistics: should we use unequal tails? *BMC Med Res Methodol*. 2016;16(1):118. doi:10.1186/s12874-016-0219-y
- 16. Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. *Stat Med.* 2003;22(17):2693-2710. doi:10.1002/sim.1482
- 17. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med.* 2002;21(11):1539-1558. doi:10.1002/sim.1186
- Rao G, Lopez-Jimenez F, Boyd J, et al. Methodological Standards for Meta-Analyses and Qualitative Systematic Reviews of Cardiac Prevention and Treatment Studies: A Scientific Statement From the American Heart Association. *Circulation*. 2017;136(10):e172-e194. doi:10.1161/CIR.00000000000523
- Misra P, Mini G, Thankappan K. Risk factor profile for non-communicable diseases among Mishing tribes in Assam, India: results from a WHO STEPs survey. *Indian J Med Res*. 2014;140(3). Accessed January 4, 2022. https://pubmed.ncbi.nlm.nih.gov/25366204/
- 20. Kusuma Y, Gupta S, Pandav C. Treatment seeking behaviour in hypertension: factors associated with awareness and medication among socioeconomically disadvantaged migrants in Delhi, India PubMed. Accessed January 4, 2022. https://pubmed.ncbi.nlm.nih.gov/24308208/
- 21. Yadav, Chaturvedi, Grover. Prevalence, awareness, treatment and control of hypertension among the elderly in a resettlement colony of Delhi. *Indian Heart J*. 2008;60(4). Accessed January 4, 2022. https://pubmed.ncbi.nlm.nih.gov/19242008/
- 22. Prayag A, Patil S, Kambar S. Implication of the Rule of Halves for Hypertension in an Urban Area, Belagavi. *Indian J Public Health Res Dev.* 2017;8:49. doi:10.5958/0976-5506.2017.00081.X
- 23. Sathish T, Kannan S, Sarma PS, Razum O, Thankappan KR. Incidence of hypertension and its risk factors in rural Kerala, India: a community-based cohort study PubMed. Accessed January 4, 2022. https://pubmed.ncbi.nlm.nih.gov/22133670/
- 24. Karmakar N, Kaushik N, Indranil S, Ramanathan P, Manas P, Rabindranath S. Awareness, treatment, and control of hypertension among adult population in a rural community of Singur block, Hooghly District, West Bengal. *J Educ Health Promot*. 2018;7. doi:10.4103/jehp_jehp_164_18

- 25. Begam NS, Kannan S, Mini G. Is Migration Affecting Prevalence, Awareness, Treatment and Control of Hypertension of Men in Kerala, India? *J Immigr Minor Health*. 2016;18(6). doi:10.1007/s10903-016-0353-y
- 26. Bhardwaj R, Arvind K, Rajeev M, et al. Prevalence, awareness and control of hypertension in rural communities of Himachal Pradesh - PubMed. Accessed January 4, 2022. https://pubmed.ncbi.nlm.nih.gov/21121207/
- 27. Gupta S, Rakesh K, Mani K, Baridalyne N, Shashi K, Sanjeev Kumar G. Prevalence, awareness, treatment, and control of diabetes and hypertension among elderly persons in a rural area of Ballabgarh, Haryana. *J Fam Med Prim Care*. 2020;9(2). doi:10.4103/jfmpc.jfmpc_1057_19
- Busingye D, Arabshahi S, Evans RG, et al. Factors associated with awareness, treatment and control of hypertension in a disadvantaged rural Indian population. *J Hum Hypertens*. 2017;31(5):347-353. doi:10.1038/jhh.2016.85
- 29. Reddy BM, Ganguly E, Sharma PK. Hypertension and its Correlates in the Oldest Old Population Aged 80 Years and Above in Urban South India. *J Gerontol Geriatr Res*. 2018;7(3):472. doi:10.4172/2167-7182.1000472
- 30. Sandhya G, Abraham A, Beegam R. Prevalence, Control and Associated Factors of Hypertension in Rural Middle Aged Women of Kerala. *Indian J Public Health Res Dev.* 2018;9:193. doi:10.5958/0976-5506.2018.00638.1
- 31. Mohan V, Deepa M, Farooq S, Datta M, Deepa R. Prevalence, awareness and control of hypertension in Chennai--The Chennai Urban Rural Epidemiology Study (CURES-52) -PubMed. Accessed January 4, 2022. https://pubmed.ncbi.nlm.nih.gov/17844691/
- 32. Chaturvedi S, Pant M, Neelam, Yadav G. Hypertension in Delhi: prevalence, awareness, treatment and control. *Trop Doct*. 2007;37(3):142-145. doi:10.1258/004947507781524593
- 33. Goswami AK, Sanjeev Kumar G, Mani K, Baridalyne Nongkynrih N. Burden of Hypertension and Diabetes among Urban Population Aged ≥ 60 years in South Delhi: A Community Based Study - PubMed. Accessed January 4, 2022. https://pubmed.ncbi.nlm.nih.gov/27134900/
- 34. Hazarika NC, Narain K, Biswas D, Kalita HC, Mahanta J. Hypertension in the native rural population of Assam. *Natl Med J India*. 2004;17(6). Accessed January 4, 2022. https://pubmed.ncbi.nlm.nih.gov/15736549/
- 35. Babu V, Sahu SK, Kanungo S. Hypertension control status and quality of care for hypertension among patients availing treatment from private sector: A cross-sectional study in urban field practice area of JIPMER, Puducherry. J Fam Med Prim Care. 2019;8(1):72-76. doi:10.4103/jfmpc.jfmpc_248_18


- Mini GK, Sarma PS, Priya C, Thankappan KR. Control of hypertension among teachers in schools in Kerala (CHATS-K), India. *Indian Heart J*. 2020;72(5):416-420. doi:10.1016/j.ihj.2020.06.005
- 37. Anupama YJ, Hegde SN, Uma G, Patil M. Hypertension is an important risk determinant for chronic kidney disease: results from a cross-sectional, observational study from a rural population in South India. *J Hum Hypertens*. 2017;31(5):327-332. doi:10.1038/jhh.2016.81
- Dandge S, Jeemon P, Reddy PS. Technology enabled non-physician health workers extending telemedicine to rural homes to control hypertension and diabetes (TETRA): A prepost demonstration project in Telangana, India. *PLOS ONE*. 2019;14(2):e0211551. doi:10.1371/journal.pone.0211551
- 39. Mallik D, Mukhopadhyay DK, Kumar P, Sinhababu A. Hypertension, Prehypertension and Normotension among Police Personnel in a District of West Bengal, India. *J Assoc Physicians India*. 2014;62(11):12-16.
- 40. Kaur P, Rao SR, Venkatachalam R, Kaliaperumal K. Hypertension treatment and control in a rural cohort in Thiruvallur, Tamil Nadu, India. *Indian J Public Health*. 2016;60(4):298-301. doi:10.4103/0019-557X.195861
- 41. Thankappan KR, Sivasankaran S, Sarma PS, et al. Prevalence-correlates-awarenesstreatment and control of hypertension in kumarakom, kerala: baseline results of a community-based intervention program. *Indian Heart J*. 2006;58(1):28-33.
- 42. Bharucha NE, Kuruvilla T. Hypertension in the Parsi community of Bombay: a study on prevalence, awareness and compliance to treatment. *BMC Public Health*. 2003;3:1. doi:10.1186/1471-2458-3-1
- 43. Roy A, Praveen PA, Amarchand R, et al. Changes in hypertension prevalence, awareness, treatment and control rates over 20 years in National Capital Region of India: results from a repeat cross-sectional study. *BMJ Open*. 2017;7(7):e015639. doi:10.1136/bmjopen-2016-015639
- 44. Kaur P, Rao SR, Radhakrishnan E, Rajasekar D, Gupte MD. Prevalence, awareness, treatment, control and risk factors for hypertension in a rural population in South India. *Int J Public Health*. 2012;57(1):87-94. doi:10.1007/s00038-011-0303-3
- 45. Tripathy JP, Thakur JS, Jeet G, Chawla S, Jain S. Alarmingly high prevalence of hypertension and pre-hypertension in North India-results from a large cross-sectional STEPS survey. *PloS One*. 2017;12(12):e0188619. doi:10.1371/journal.pone.0188619
- 46. Chacko S, Jeemon P. Role of family support and self-care practices in blood pressure control in individuals with hypertension: results from a cross-sectional study in Kollam District, Kerala. Published online July 28, 2020. doi:10.12688/wellcomeopenres.16146.1

- 47. Gupta R, Pandey RM, Misra A, et al. High prevalence and low awareness, treatment and control of hypertension in Asian Indian women. *J Hum Hypertens*. 2012;26(10):585-593. doi:10.1038/jhh.2011.79
- 48. Kanungo S, Mahapatra T, Bhowmik K, et al. Patterns and predictors of undiagnosed and uncontrolled hypertension: observations from a poor-resource setting. *J Hum Hypertens*. 2017;31(1):56-65. doi:10.1038/jhh.2016.30
- 49. Gabert R, Ng M, Sogarwal R, et al. Identifying gaps in the continuum of care for hypertension and diabetes in two Indian communities. *BMC Health Serv Res*. 2017;17(1):846. doi:10.1186/s12913-017-2796-9
- 50. Gupta A, Gupta R, Sharma KK, et al. Prevalence of diabetes and cardiovascular risk factors in middle-class urban participants in India. *BMJ Open Diabetes Res Care*. 2014;2(1):e000048. doi:10.1136/bmjdrc-2014-000048
- 51. Moser KA, Agrawal S, Davey Smith G, Ebrahim S. Socio-demographic inequalities in the prevalence, diagnosis and management of hypertension in India: analysis of nationally-representative survey data. *PloS One*. 2014;9(1):e86043. doi:10.1371/journal.pone.0086043
- 52. Gupta R, Deedwania PC, Achari V, et al. Normotension, prehypertension, and hypertension in urban middle-class subjects in India: prevalence, awareness, treatment, and control. *Am J Hypertens*. 2013;26(1):83-94. doi:10.1093/ajh/hps013
- 53. Banerjee S, Mukherjee TK, Basu S. Prevalence, awareness, and control of hypertension in the slums of Kolkata. *Indian Heart J.* 2016;68(3):286-294. doi:10.1016/j.ihj.2015.09.029
- 54. Prenissl J, Manne-Goehler J, Jaacks LM, et al. Hypertension screening, awareness, treatment, and control in India: A nationally representative cross-sectional study among individuals aged 15 to 49 years. *PLoS Med.* 2019;16(5):e1002801. doi:10.1371/journal.pmed.1002801
- 55. Barker TH, Migliavaca CB, Stein C, et al. Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence. *BMC Med Res Methodol*. 2021;21(1):189. doi:10.1186/s12874-021-01381-z
- 56. Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted? *Stat Med.* 2002;21(11):1559-1573. doi:10.1002/sim.1187
- Maulik PK, Mascarenhas MN, Mathers CD, Dua T, Saxena S. Prevalence of intellectual disability: A meta-analysis of population-based studies. *Res Dev Disabil*. 2011;32(2):419-436. doi:10.1016/j.ridd.2010.12.018
- 58. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315(7109):629-634. doi:10.1136/bmj.315.7109.629

- 59. Anchala R, Kannuri NK, Pant H, et al. Hypertension in India: a systematic review and metaanalysis of prevalence, awareness, and control of hypertension. *J Hypertens*. 2014;32(6):1170-1177. doi:10.1097/HJH.000000000000146
- 60. National Programme for prevention & Control of Cancer, Diabetes, Cardiovascular Diseases & stroke (NPCDCS)□:: National Health Mission. Accessed January 8, 2022. https://nhm.gov.in/index1.php?lang=1&level=2&sublinkid=1048&lid=604
- 61. Kaur P, Kunwar A, Sharma M, et al. India Hypertension Control Initiative—Hypertension treatment and blood pressure control in a cohort in 24 sentinel site clinics. *J Clin Hypertens*. 2020;23(4):720-729. doi:10.1111/jch.14141
- 62. Geldsetzer P, Manne-Goehler J, Marcus ME, et al. The state of hypertension care in 44 lowincome and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1.1 million adults. *The Lancet*. 2019;394(10199):652-662. doi:10.1016/S0140-6736(19)30955-9
- 63. Dhungana RR, Pandey AR, Shrestha N. Trends in the Prevalence, Awareness, Treatment, and Control of Hypertension in Nepal between 2000 and 2025: A Systematic Review and Meta-Analysis. *Int J Hypertens*. 2021;2021:6610649. doi:10.1155/2021/6610649
- 64. Riaz M, Shah G, Asif M, Shah A, Adhikari K, Abu-Shaheen A. Factors associated with hypertension in Pakistan: A systematic review and meta-analysis. *PLOS ONE*. 2021;16(1):e0246085. doi:10.1371/journal.pone.0246085
- 65. Husain MJ, Datta BK, Kostova D, et al. Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability. *J Am Heart Assoc*. 2020;9(9):e015302. doi:10.1161/JAHA.119.015302
- 66. Pathni AK, Sahoo SK, Moran AE, et al. Unmet Need for Hypertension Treatment in India: Evidence from Hypertension Drugs Market Data. *Glob Heart*. 16(1):26. doi:10.5334/gh.973
- 67. Mohanty SK, Pedgaonkar SP, Upadhyay AK, et al. Awareness, treatment, and control of hypertension in adults aged 45 years and over and their spouses in India: A nationally representative cross-sectional study. *PLOS Med.* 2021;18(8):e1003740. doi:10.1371/journal.pmed.1003740



Study Control rate [95%.C.I.] 13.76 [10.63; 16.89] Bharucha;2003 17.90 [12.94; 22.87] Hazarika;2004 Thankappan;2006 26.02 [21.93; 30.11] 32.47 [25.07; 39.86] Mohan;2007 Chaturvedi;2007a 19.66 [13.82; 25.50] Chaturvedi;2007b 15.75 [12.09; 19.41] 26.42 [22.78; 30.06] Kaur;2012 41.98 [38.39; 45.56] Gupta;2012 44.32 [41.79; 46.84] Gupta;2013 26.23 [21.29; 31.17] Mallik;2014



 Gupta;2014
 28

 Moser;2014
 45

 Goswami;2016
 32

 Kaur;2016
 43

 Banerjee;2016
 17

 Busingye;2017
 62

 Anupama;2017
 14

 Roy;2017
 33

 Tripathy;2017
 67

 Kanungo;2017
 27

 Gabert;2017
 40


 Reddy;2018
 38


 Sandhya;2018
 43

 Veena;2019
 43

 Dandge;2019
 46

28.47 [25.77; 31.16] 45.59 [42.89; 48.28] 32.99 [26.43; 39.56] 43.07 [37.80; 48.34] 11.70 [10.74; 12.66] 62.71 [53.99; 71.44] 14.46 [10.09; 18.83] 33.21 [29.27; 37.15] 61.05 [57.18; 64.91] 27.70 [24.52; 30.89] 40.99 [37.72; 44.27] 35.56 [27.48; 43.63] 43.05 [35.15; 50.94] 43.91 [37.50; 50.33]46.83 [40.66; 52.99]





Sex